Breast Cancer Stem Cells: Therapy Resistance and Novel Therapeutic Targets
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 June 2019) | Viewed by 103267
Special Issue Editor
Interests: triple-negative breast cancer; cancer stem cells; aldehyde dehydrogenase 1A3; retinoic acid signaling; precision medicine; therapy resistance; lncRNA
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
As with other cancers, increasing evidence supports the significance of breast cancer stem cells (CSCs) in the development and progression of breast cancer. Importantly, these cancer drivers also share many of the characteristics of stem cells, including qualities that make them resistant to commonly used cancer treatments. Mechanisms such as increased efflux capacity, higher levels of detoxifying enzymes, enhanced DNA repair, a slower cell-cycle, and increased activation of the embryonic signaling pathways (Notch, Wnt, and Hedgehog) give CSCs an increased resistance to chemotherapeutics and radiation. Clinical evidence also suggests that CSC resistance may contribute to breast tumor recurrence and poorer patient outcomes. Therefore, the development of adjuvant therapies that either target CSCs or sensitize CSCs to chemotherapies has been a major focus of recent drug discovery in the treatment of cancer. We invite original research or review articles that address the mechanisms of breast CSC therapy resistance and anti-breast CSC drug development.
Dr. Paola Marcato
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- cancer stem cells
- therapy
- resistance
- recurrence